GSK1349572 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

In August 2013, the US FDA approved dolutegravir (also referred to as S/GSK1349572) for the treatment of HIV-1 infection in adults and children ages 12 years and older in combination with other antiretroviral drugs. Dolutegravir was approved in Canada in November 2013. HIV/AIDS remains a global epidemic with 35 million people infected, including 2.3 million new infections as of 2012. Dolutegravir joins raltegravir and elvitegravir (this chapter of ARMC) as the latest of three FDA-approved HIV integrase strand transfer inhibitors (INSTIs). Dolutegravir was discovered by rational design from a literature diketo acid HIV integrase inhibitor utilizing X-ray coordinates to predict ideal bond angles between the diketone and distal benzyl group. In dolutegravir, the monocyclic component of the reported inhibitor was replaced with the tricyclic carbamoyl pyridone moiety. The researchers postulated that the appropriate arrangement of three oxygens would permit chelation with two magnesium ions in the binding site thus affording improved potency. Ultimately, this arrangement along with further modifications afforded dolutegravir, a potent inhibitor of HIV integrase (IC₅₀=1.7 nM).

Chemische Eigenschaften

White Solid

Definition

ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]ox zine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1.

GSK1349572 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

GSK1349572 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
AFINE CHEMICALS LIMITED	+86-571-85134551	info@afinechem.com	China	15081	58
Guangzhou Tengyue Chemical Co., Ltd.	+86-86-18148706580 +8618826483838	evan@tyvovo.com	China	143	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29640	60
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
Nanjing Finetech Chemical Co., Ltd.	025-85710122 17714198479	sales@fine-chemtech.com	CHINA	885	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
Lianyungang happen teng technology co., LTD	15950718863	wang666xt@163.com	CHINA	295	58
career henan chemical co	+86-0371-86658258 +8613203830695	sales@coreychem.com	China	29812	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	965	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19936	58

1051375-16-6()Verwandte Suche:

---

• 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-
• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide Dolutegravir (GSK1349572)
• GSK1349572, S-349572, GSK572
• (4R,12aS)-N-(2,4-Difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• Dolutegravir, >=98%
• Dolutegravir free acid
• GSK1349572
• (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• S/GSK1349572 (GSK1349572)
• GSK1349572(dolutegravir)
• dolutegravir/GSK1349572/S-349572
• Dolutegravir (S/GSK1349572
• CS-9
• Dolutegravir - GSK 1349572 | Soltegravir | Tivicay
• BNKY001-DL04
• S/GSK1349572 (Dolutegravir)
• 134413
• Dolutegravir DTG
• (3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxo-4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-13-carboxamide
• Pharmaceutical ingredient against HIV GSK1349572
• GSK1349572 USP/EP/BP
• Dolutegravir (0.1 mg/mL in Methanol)
• Dolutegravir D3Q: What is Dolutegravir D3 Q: What is the CAS Number of Dolutegravir D3 Q: What is the storage condition of Dolutegravir D3 Q: What are the applications of Dolutegravir D3
• DolutegravirQ: What is Dolutegravir Q: What is the CAS Number of Dolutegravir Q: What is the storage condition of Dolutegravir Q: What are the applications of Dolutegravir
• Dolutegravir Tablet
• Dolutegravi
• S/GSK1349572
• Dulutegravir
• The degree of root wei
• Dolutegravir,HIV Integrase,HIV,inhibit,Human immunodeficiency virus,Inhibitor
• (4R, 12aS) - N - [(2,4-difluorophenyl) methyl] -3,4,6,8,12,12a - hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyridino [1 ', 2': 4,5] pyrazino [2,1-b] [1,3] oxazin-9-formamide
• S-349572
• Dolutegravir Impurity 40
• Dotiravir Impurity 1
• (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
• Dolutegravir Impurity L
• Dolutevir
• Dolutegravir, HIV integrase inhibitor
• Dolutegravir, 10 mM in DMSO
• Dolutegravir, 98%min
• D5-Dolutegravir
• 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)- (Intermediate of Dolutegravir sodium)
• Dolutegravir API
• Dolutegravir (GSK1349572)
• Dolutegravir
• 1051375-16-6
• 10513375-16-6
• 134678-17-8
• C20H19F2N3O5
• API
• Inhibitors
• HIV-1 integrase inhibitor
• Inhibitor
• CMLLYL
• 1051375-16-6